NZ539936A - Transdermal buprenorphine dosage regimen for analgesia - Google Patents

Transdermal buprenorphine dosage regimen for analgesia

Info

Publication number
NZ539936A
NZ539936A NZ539936A NZ53993603A NZ539936A NZ 539936 A NZ539936 A NZ 539936A NZ 539936 A NZ539936 A NZ 539936A NZ 53993603 A NZ53993603 A NZ 53993603A NZ 539936 A NZ539936 A NZ 539936A
Authority
NZ
New Zealand
Prior art keywords
buprenorphine
dosage form
patient
btds
dosage
Prior art date
Application number
NZ539936A
Other languages
English (en)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NZ539936A publication Critical patent/NZ539936A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ539936A 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia NZ539936A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Publications (1)

Publication Number Publication Date
NZ539936A true NZ539936A (en) 2007-06-29

Family

ID=32595187

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ539936A NZ539936A (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Country Status (16)

Country Link
US (1) US7270830B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572167B1 (cg-RX-API-DMAC7.html)
JP (2) JP5054893B2 (cg-RX-API-DMAC7.html)
AT (1) ATE400258T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003297073A1 (cg-RX-API-DMAC7.html)
CA (1) CA2510223C (cg-RX-API-DMAC7.html)
CY (1) CY1108384T1 (cg-RX-API-DMAC7.html)
DE (1) DE60322102D1 (cg-RX-API-DMAC7.html)
DK (1) DK1572167T3 (cg-RX-API-DMAC7.html)
ES (1) ES2310262T3 (cg-RX-API-DMAC7.html)
IL (1) IL169056A (cg-RX-API-DMAC7.html)
MX (1) MXPA05006334A (cg-RX-API-DMAC7.html)
NZ (1) NZ539936A (cg-RX-API-DMAC7.html)
PT (1) PT1572167E (cg-RX-API-DMAC7.html)
SI (1) SI1572167T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004054553A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637073B2 (en) 2003-07-25 2014-01-28 Purdue Pharma L.P. Treatment of dependence withdrawal

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
BRPI0409945A (pt) * 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
CA2529983C (en) * 2003-07-25 2010-07-20 Euro-Celtique S.A. Preoperative treatment of post operative pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US9522188B2 (en) * 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2010047681A1 (en) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
MX2018010367A (es) * 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
WO2020124073A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
AU637496B2 (en) 1990-04-24 1993-05-27 Teijin Limited Plaster
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
PT1485051E (pt) 2002-03-20 2008-07-09 Euro Celtique Sa Processo de administração da buprenorfina para o tratamento da depressão
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637073B2 (en) 2003-07-25 2014-01-28 Purdue Pharma L.P. Treatment of dependence withdrawal

Also Published As

Publication number Publication date
JP2006513184A (ja) 2006-04-20
PT1572167E (pt) 2008-10-03
CA2510223C (en) 2017-09-12
DK1572167T3 (da) 2008-10-13
ATE400258T1 (de) 2008-07-15
JP5054893B2 (ja) 2012-10-24
AU2010201479A1 (en) 2010-05-06
ES2310262T3 (es) 2009-01-01
SI1572167T1 (sl) 2008-12-31
US20040126416A1 (en) 2004-07-01
AU2003297073A1 (en) 2004-07-09
JP2010285457A (ja) 2010-12-24
WO2004054553A9 (en) 2005-09-15
WO2004054553A1 (en) 2004-07-01
EP1572167A1 (en) 2005-09-14
DE60322102D1 (de) 2008-08-21
EP1572167B1 (en) 2008-07-09
EP1572167A4 (en) 2007-01-10
CY1108384T1 (el) 2014-02-12
IL169056A (en) 2012-01-31
MXPA05006334A (es) 2005-08-26
CA2510223A1 (en) 2004-07-01
AU2010201479B2 (en) 2012-11-01
US7270830B2 (en) 2007-09-18

Similar Documents

Publication Publication Date Title
AU2010201479B2 (en) Transdermal buprenorphine dosage regimen for analgesia
AU2013359017B2 (en) Methods for treating pruritus
US8987289B2 (en) Methods for treating pruritus
US20030181475A1 (en) Method of administering buprenorphine to treat depression
GB2447015A (en) Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
US8637538B1 (en) Methods for treatment of pruritis
US8637073B2 (en) Treatment of dependence withdrawal
US20150359789A1 (en) Methods for treating pruritus
US8940753B1 (en) Methods for treating pruritis
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
US7413748B2 (en) Transdermal buprenorphine to treat pain in sickle cell crisis
EP1913938A1 (en) Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) Transdermal buprenorphine dosage regimen for treatment of diarrhea
HK1119563A (en) Transdermal buprenorphine dosage regimen for analgesia
AU2013200522A1 (en) Transdermal buprenorphine dosage regimen for analgesia
US20040228906A1 (en) Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
AU774779B2 (en) Method of providing sustained analgesia with buprenorphine
AU2013204227B2 (en) Method of providing sustained analgesia with buprenorphine
Ghodse et al. Opioid analgesics and narcotic antagonists
AU2012244363A1 (en) Method of providing sustained analgesia with buprenorphine
MXPA06004905A (en) Transdermal analgesic systems having reduced abuse potential

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 DEC 2016 BY THOMSON REUTERS

Effective date: 20130920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2017 BY THOMSON REUTERS

Effective date: 20161117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2018 BY ANAQUA SERVICES

Effective date: 20171120

LAPS Patent lapsed